Ambrosini G, Plescia J, Chu K C, High K A, Altieri D C
Molecular Cardiobiology Program and Department of Pathology, The Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut 06536, USA.
J Biol Chem. 1997 Mar 28;272(13):8340-5. doi: 10.1074/jbc.272.13.8340.
Binding of factor Xa to human umbilical vein endothelial cells (HUVEC) is contributed by effector cell protease receptor-1 (EPR-1). The structural requirements of this recognition were investigated. Factor Xa or catalytically inactive 5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone-factor Xa bound indistinguishably to HUVEC and EPR-1 transfectants, and inhibited equally well the binding of 125I-factor Xa to these cells. Similarly, factor Xa active site inhibitors TAP or NAP5 did not reduce ligand binding to EPR-1. A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM). In contrast, none of the other factor X peptides tested or a control peptide with the inter-EGF sequence in scrambled order was effective. A recombinant chimeric molecule expressing the factor X sequence Leu83-Leu88 within a factor IX backbone inhibited binding of 125I-factor Xa to HUVEC and EPR-1 transfectants in a dose-dependent fashion, while recombinant factor IX or plasma IXa had no effect. An antibody generated against the factor X peptide 83-88, and designated JC15, inhibited 125I-factor Xa binding to HUVEC. The JC15 antibody bound to factor Xa and the recombinant IX/X83-88 chimera in a concentration dependent manner, while no specific reactivity with factors X or IXa was observed. Furthermore, binding of 125I-factor Xa to immobilized JC15 was inhibited by molar excess of unlabeled factor Xa, but not by comparable concentrations of factors X or IXa. These findings identify the inter-EGF sequence Leu83-Leu88 in factor Xa as a novel recognition site for EPR-1, and suggest its potential role as a protease activation-dependent neo-epitope. This interacting motif may help elucidate the contribution of factor Xa to cellular assembly of coagulation and vascular injury.
凝血因子Xa与人类脐静脉内皮细胞(HUVEC)的结合是由效应细胞蛋白酶受体-1(EPR-1)介导的。本研究探讨了这种识别的结构要求。凝血因子Xa或催化失活的5-二甲基氨基萘-1-磺酰基(丹磺酰)-谷氨酸-甘氨酸-精氨酸-(DEGR)-氯甲基酮-凝血因子Xa与HUVEC和EPR-1转染细胞的结合无明显差异,并且对125I-凝血因子Xa与这些细胞的结合抑制效果相同。同样,凝血因子Xa活性位点抑制剂TAP或NAP5也不会降低配体与EPR-1的结合。一条复制表皮生长因子(EGF)序列间Leu83-Phe84-Thr85-Arg86-Lys87-Leu88-(Gly)的凝血因子X肽可抑制HUVEC介导的不依赖于因子V/Va的凝血酶原激活,并以剂量依赖方式阻断125I-凝血因子Xa与这些细胞的结合(半数抑制浓度约为20-40 microM)。相比之下,所测试的其他凝血因子X肽或表皮生长因子序列顺序打乱的对照肽均无效。一种在凝血因子IX骨架内表达凝血因子X序列Leu83-Leu88的重组嵌合分子以剂量依赖方式抑制125I-凝血因子Xa与HUVEC和EPR-1转染细胞的结合,而重组凝血因子IX或血浆IXa则无此作用。一种针对凝血因子X肽83-88产生的名为JC15的抗体可抑制125I-凝血因子Xa与HUVEC的结合。JC15抗体以浓度依赖方式与凝血因子Xa和重组IX/X83-88嵌合体结合,而未观察到与凝血因子X或IXa的特异性反应。此外,过量未标记的凝血因子Xa可抑制125I-凝血因子Xa与固定化JC15的结合,而同等浓度的凝血因子X或IXa则无此作用。这些发现确定了凝血因子Xa中的表皮生长因子序列间Leu83-Leu88是EPR-1的一个新识别位点,并提示其作为蛋白酶激活依赖性新表位的潜在作用。这种相互作用基序可能有助于阐明凝血因子Xa在凝血细胞组装和血管损伤中的作用。